Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175077 | 1.00 | LTA4H (0.41) | LTA4HSIGMAR1NCF1MAOB | |
| SCHEMBL7021205 | 1.00 | LTA4H (0.41) | LTA4HSIGMAR1NCF1MAOB | |
| SCHEMBL27706864 | 0.88 | LTA4H (0.40) | LTA4HSIGMAR1MAOB | |
| SCHEMBL2459174 | 0.86 | LTA4H (0.42) | LTA4HSIGMAR1 | |
| SCHEMBL14995124 | 0.86 | — | — | |
| SCHEMBL2459177 | 0.86 | LTA4H (0.42) | LTA4HSIGMAR1 | |
| SCHEMBL8327456 | 0.85 | L3MBTL1 (0.42) | LTA4HMAOB | |
| SCHEMBL22792813 | 0.84 | LTA4H (0.44) | LTA4HSIGMAR1 | |
| SCHEMBL1194198 | 0.84 | LTA4H (0.41) | LTA4HSIGMAR1 | |
| SCHEMBL9943884 | 0.84 | LTA4H (0.41) | LTA4HSIGMAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| EP-3294729-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
| US-8273905-B2 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | ABBOTT PRODUCTS GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| US-7919507-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2011-04-05 | — | — | US | disclosed |
| EP-1871758-B1 | AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS | ABBOTT PRODUCTS GMBH (DE) | 2010-08-25 | — | — | EP | disclosed |
| US-7741329-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| US-7714150-B2 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090203686-A1 | Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.I.C. | 2009-04-09 | — | — | US | disclosed |
| EP-1385845-B1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2008-01-09 | — | — | EP | disclosed |
| US-20060252821-A1 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | SOLVAY PHARMACEUTICALS GMBH | 2006-11-09 | — | — | US | disclosed |
| US-6943160-B2 | Morpholine derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2005-09-13 | — | — | US | disclosed |
| EP-1353918-B1 | MORPHOLINE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2005-01-12 | — | — | EP | disclosed |
| US-20040143115-A1 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| US-20040058921-A1 | Morpholine derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1385845-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2004-02-04 | — | — | EP | disclosed |
| EP-1353918-A1 | MORPHOLINE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002090355-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002044172-A1 | MORPHOLINE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | LTA4H 1852/4885SIGMAR1 347/4885NCF1 665/4885 |
| US-20060252821-A1 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ABCC9 | LTA4H 2392/4885SIGMAR1 133/4885NCF1 3678/4885 |
| US-20090203686-A1 | Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ARG1 | LTA4H 2275/4885SIGMAR1 127/4885NCF1 3932/4885 |
| US-20040143115-A1 | N-aroyl cyclic amines | HCRTR1, HCRTR2, CNR1 | LTA4H 3054/4885SIGMAR1 48/4885NCF1 1600/4885 |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | LTA4H 2016/4885SIGMAR1 4495/4885NCF1 892/4885 |
| US-20040058921-A1 | Morpholine derivatives as antagonists of orexin receptors | HCRTR2, HCRTR1, OXTR | LTA4H 1070/4885SIGMAR1 111/4885NCF1 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.